Proceedings: Human Leukocyte Antigen Haplo-Homozygous Induced Pluripotent Stem Cell Haplobank Modeled After the California Population: Evaluating Matching in a Multiethnic and Admixed Population
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Summary The development of a California-based induced pluripotent stem cell (iPSC) bank based on human leukocyte antigen (HLA) haplotype matching represents a significant challenge and a valuable opportunity for the advancement of regenerative medicine. However, previously published models of iPSC banks have neither addressed the admixed nature of populations like that of California nor evaluated the benefit to the population as a whole. We developed a new model for evaluating an iPSC haplobank based on demographic and immunogenetic characteristics reflecting California. The model evaluates haplolines or cell lines from donors homozygous for a single HLA-A, HLA-B, HLA-DRB1 haplotype. We generated estimates of the percentage of the population matched under various combinations of haplolines derived from six ancestries (black/African American, American Indian, Asian/Pacific Islander, Hispanic, and white/not Hispanic) and data available from the U.S. Census Bureau, the California Institute for Regenerative Medicine, and the National Marrow Donor Program. The model included both cis (haplotype-level) and trans (genotype-level) matching between a modeled iPSC haplobank and the recipient population following resampling simulations. We showed that serving a majority (>50%) of a simulated California population through cis matching would require the creation, redundant storage, and maintenance of almost 207 different haplolines representing the top 60 most frequent haplotypes from each ancestry group. Allowances for trans matching reduced the haplobank to fewer than 141 haplolines found among the top 40 most frequent haplotypes. Finally, we showed that a model optimized, custom haplobank was able to serve a majority of the California population with fewer than 80 haplolines. Significance Induced pluripotent stem cell (iPSC) technology offers the promise of cellular therapies for a wide variety of diseases and injuries. Should these clinical trials be successful, it will be necessary to consider what it would take to deliver these novel treatments to the large numbers of patients who will need them. The use of allogeneic iPSC cell lines for derivation of grafts for transplantation has been considered; however, in order to avoid graft rejection by the allogeneic host, immunological compatibility between graft and host need to be considered. Creation of a haplobank of iPSC lines homozygous for a variety of HLA types, representative of different geographic populations and ethnic groups, could simplify HLA matching and provide matches for reasonable percentages of target populations and extend iPSC-derived therapies beyond the autologous setting. To that end, the rationale for the current study was that the genetic diversity of California's population might be a considerable advantage in establishing a representative “world bank” compared with banking from countries in which populations have more uniform ancestry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In regions such as California, USA, a population with highly diverse HLA haplotypes, approximately 80 iPSC lines from donors with different ancestry groups will be required to reach 50% coverage of the population [108].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Taylor, C. J., Bolton, E. M., Pocock, S., Sharples, L. D., Pedersen, R. A., & Bradley, J. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67813-0 · Cited by 493
Gragert, L., Madbouly, A., Freeman, J., & Maiers, M. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.06.025 · Cited by 421
Fallin, D., & Schork, N. J. (2000) · The American Journal of Human Genetics · doi:10.1086/303069 · Cited by 408
Progress toward the clinical application of patient-specific pluripotent stem cells
Kiskinis, E., & Eggan, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40553 · Cited by 339
Gourraud, P.-A., Gilson, L., Girard, M., & Peschanski, M. (2012) · Stem Cells · doi:10.1002/stem.772 · Cited by 163
Self-citationOptimal HLA matching in hematopoietic cell transplantation
Petersdorf, E. W. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.014 · Cited by 161
Minor histocompatibility antigens
Perreault, C., Décary, F., Brochu, S., Gyger, M., Bélanger, R., & Roy, D.-C. (1990) · Blood · doi:10.1182/blood.v76.7.1269.bloodjournal7671269 · Cited by 150
Shaw, B. E., Arguello, R., García-Sepúlveda, C. A., & Madrigal, J. A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08224.x · Cited by 104
Minor histocompatibility antigens: past, present, and future
Spierings, E. (2014) · Tissue Antigens · doi:10.1111/tan.12445 · Cited by 101
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT
Warren, E. H., Zhang, X. C., Li, S., Fan, W., Storer, B. E., Chien, J. W., Boeckh, M. J., Zhao, L. P., Martin, P. J., & Hansen, J. A. (2012) · Blood · doi:10.1182/blood-2012-04-347286 · Cited by 93
The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell-derived Therapies
Scheiner, Z. S., Talib, S., & Feigal, E. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.509588 · Cited by 82
Self-citationEmbryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Lui, K. O., Waldmann, H., & Fairchild, P. J. (2009) · Current Stem Cell Research & Therapy · doi:10.2174/157488809787169093 · Cited by 63
Inferred HLA Haplotype Information for Donors From Hematopoietic Stem Cells Donor Registries
Gourraud, P., Lamiraux, P., Kadhi, N. E., RAFFOUX, C., & Cambon‐Thomsen, A. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.01.011 · Cited by 48
Self-citationImmunogenicity and Allogenicity: A Challenge of Stem Cell Therapy
Charron, D. J., Suberbielle, C., & Al‐Daccak, R. (2008) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-008-9062-9 · Cited by 42
Ruggeri, A., Ciceri, F., Gluckman, É., Labopin, M., & Rocha, V. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.06.002 · Cited by 40
Gourraud, P., Génin, E., & Cambon‐Thomsen, A. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201233 · Cited by 29
Self-citationEberhard, H., Madbouly, A. S., Gourraud, P., Balère, M.-L., Feldmann, U., Gragert, L. A., Maldonado-Torres, H., Pingel, J., Schmidt, A. H., Steiner, D., et al. (2013) · Tissue Antigens · doi:10.1111/tan.12160 · Cited by 26
Self-citationMaiers, M. J., Gragert, L. A., Madbouly, A. S., Steiner, D., Marsh, S. G. E., Gourraud, P., Oudshoorn, M., van der Zanden, H., Schmidt, A. H., Pingel, J., et al. (2012) · International Journal of Immunogenetics · doi:10.1111/iji.12031 · Cited by 21
Self-citationPappas, D. J., Tomich, A., Garnier, F., Marry, É., & Gourraud, P. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.01.029 · Cited by 20
Self-citationAllogenicity & immunogenicity in regenerative stem cell therapy.
Charron, D. J. (2013) · PubMed Central · Cited by 18
Research works printed but not linked: 1
- T ommunit Uniting Researchers & Resources: he STEM CELLS Journal Online C y Uniting Researchers & Resources:The STEM CELLS Journal Online Community http://StemCellsPortal.com/content/2015-0052
Cited by
Lee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
Accelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97
The clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0190-2 · Cited by 77
Rim, Y. A., Park, N., Nam, Y., Ham, D., Kim, J., Ha, H., Jung, J., Jung, S. M., Baek, I. C., Kim, S., et al. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2578 · Cited by 70
Metadata
- Authors
- Pappas, D. J., Gourraud, P.-A., Le Gall, C., Laurent, J., Trounson, A., DeWitt, N., & Talib, S.
- Affiliations
- Methodomics, Mortagne-sur-Sevre, France
- University of California, San Francisco (US)
- Institut Supérieur des Biotechnologies de Paris (FR)
- California Institute for Regenerative Medicine (US)
- Corresponding author
- Gourraud, Pierre-Antoine
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-13
- Volume
- 4
- Issue
- 5
- Pages
- 413-418
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- PMC
- PMC4414226
- OpenAlex
- W2097085702
- Cited by
- 57
- References
- 22
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 2 · 2022: 9 · 2021: 6 · 2020: 12 · 2019: 9 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 3
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells Translational Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- California Institute for Regenerative Medicine
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Forensic and Genetic Research
- Keywords
- HLA haplotype matching, admixed populations, California population, ancestry groups, haplotype frequencies, graft rejection, immunological compatibility
- MeSH terms
- California, Cell Line, Ethnicity, Genetics, Population, Genotype, Haplotypes, Histocompatibility Testing, HLA Antigens, Homozygote, Humans, Tissue Donors, Induced Pluripotent Stem Cells, Stem Cell Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.